Emerging pharmacotherapy for obesity

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 587-596

  Aronne, Louis J ^a   Powell, Amanda G ^b   Apovian, Caroline M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT receptor agonist; anorectic; appetite suppressant; glucagon like peptide analogs; obesity; pancreatic lipase inhibitor; weight loss

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTIOBESITY AGENT; AZD 7687; CETILISTAT; EMPATIC; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GSK 598809; LEPTIN; LIRAGLUTIDE; LORCASERIN; METRELEPTIN; METRELEPTIN PLUS PRAMLINTIDE; OBINEPITIDE; PHENTERMINE PLUS TOPIRAMATE; PP 1420; PRAMLINTIDE; PRX 0093; PSN 821; TESOFENSINE; TETRAHYDROLIPSTATIN; TKS 1225; TSK 1225; TTP 435; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNEPERIT; ZGN 433; ZONISAMIDE;

ACUTE PANCREATITIS; AMNESIA; ATTENTION DISTURBANCE; BLURRED VISION; BODY WEIGHT; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJECTION SITE REACTION; INSOMNIA; MEMORY DISORDER; NAUSEA; OBESITY; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TASTE; THYROID MEDULLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051993850     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.609168     Document Type: Review

References (56)

1. Ogden CL, Carroll MD, McDowell MA, et al. for the Division of Health and Nutrition Examination Surveys. Obesity among adults in the United States-no statistically significant change since 2003 - 2004. NCHS Data Brief. November 2007. US Dept of Health and Human Services. Centers for Disease Control and Prevention
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999 - 2008. JAMA 2010;303(3):235-41
3. James PT, Rigby N, Leach R; for the International Obesity Task Force. The obesity epidemic metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004;11:3-8
4. World Health Organisation factsheet number 311 - obesity and overweight. Available from: Www.who.int/ mediacentre/factsheets/fs311/ en/index.html
5. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-9 This reference displays the benefits of weight loss on obesity-related co-morbidities after gastric bypass surgery, which helps highlight the notion that some of the future medical therapies may be to mimic some of the hormonal changes that occur from bariatric surgery.
6. Marsk R, Freedman J, Tynelius P, et al. Antiobesity surgery in Sweden from 1980 to 2005: A population-based study with a focus on mortality. Ann Surg 2008;248(5):777-81
7. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am 1989;73:111-38
8. Mokdad AH, Marks JD, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;29(10):1238-45
9. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6(2):97-106
10. Wing RR. Long term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53
11. Sjostrom L, Lindroos AK, Peltonen M, et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93 This reference is considered to be important due to the fact that it represents the importance of weight loss in improving the risk of diabetes. It highlights how weight reduction can have a meaningful impact on obesity-related co-morbidities.
12. Tuomilehto I, Lindstrom I, Eriksson JG, et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
13. Adams TD, Gress RE, Smith SC, et al. Long-Term mortality after gastric bypass surgery. NEJM 2007;357(8):753-61
14. Available from: Www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071612.pdf
15. Fujioka K, Lee MW. Pharmacologic treatment options for obesity: Current and potential medications. Nutr Clin Pract 2007;22:50-4
16. Padwal R, Li SK, Lau DC. Long term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003;4:CD004094
17. Cowen & Co. Therapeutic Categories Outlook- Obesity. March 2011
18. Astrup A, Caterson I, Zelissen P, et al. Topiramate: Long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658-9
19. Bray GA, Hollander P, Klein S, et al. A 6 month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-33
20. Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28(11):1399-410
21. Anderson JW, Greenway FL, Fujioka K, et al. Buproprion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41
22. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46
23. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009a;17:30-9
24. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005;8:571-8
25. Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined buproprion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009b;94:4898-906
26. Orexigen press release. Available from: Http://ir.orexigen.com/phoenix. zhtml? c=207034&p=irolnewsArticle& ID=1308920&highlight
27. Oommen KJ, Mathews S. Zonisamide, a new anti-epileptic drug. Clin Neuropharmacol 1999;22:192-200
28. Gadde KM, Yonish G, Foust MS, Wagner HR. Combination therapy of Zonisamide and Buproprion for weight reduction in obese women: A preliminary randomized open label study. J Clin Psychiatry 2007;68:1226-9
29. Fujioka K, Apovian C, Hill J. The evolution of obesity therapies: New applications for existing drugs. MedscapeCME Diabetes Endocrinology, 2010. Available from: Http://cme.medscape.com/viewarticle/ 722366
30. Myers MG, Leibel RL, Seeley RJ, Schwartz MW. Obesity and Leptin resistance: Distinguishing cause from effect. Trends Endocrinol Metab 2010;10(11):643-51
31. Lutz TA. Pancreatic Amylin as a centrally acting satiating hormone. Curr Drug Targets 2005;6:181-9
32. Lutz TA. Amylinergic control of food intake. Physiol Behav 2006;89:465-71
33. Hollander P, Maggs DG, Ruggles JA, et al. Effect of Pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12:661-8
34. Chan JL, Roth JD, Weyer C. It takes two to tango: Combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 2009;57(17):777-83
35. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/ metreleptin: An integrated neurohormonal approach to obesity. Pharmacotherapy 2009;17(9):1736-43
36. Amylin Pharmaceuticals press release. Amylin pharmaceuticals announces positive results from dose ranging clinical study of Pramlintide/Metreleptin combination treatment for obesity. Available from: Http://phx.corporate-ir. net/phoenix.zhtml?c=101911&p=irolnewsArticle& ID=1305954
37. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-8
38. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role fo valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81
39. Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35
40. Kennett GA, Clifton PG. New Approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier? Pharmacol Biochem Behav 2010;97:63-83
41. Smith SR, Weissman NJ, Anderson CM, et al. NEJM 2010;363:245-56
42. Arena Pharmaceuticals, Inc., Press Release. Arena Pharmaceuticals reports positive, highly significant BLOSSOM trial results for weight management; NDA submission on track for December. September 18th, 2009. Available from: Http://invest.arenapharm.com/ releasedetail.cfm?ReleaseID=410040 [Last accessed February 2011]
43. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151-84
44. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
45. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomized, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
46. Wadden T, Hollander P, Klein S, et al. Liraglutide provides weight maintenance and additional weight loss after low-calorie diet-induced weight loss in obese subjects without diabetes: The SCALE maintenance study. Presented at the American Diabetes Association's 71st Scientific Sessions, 24 - 28 June 2011, San Diego, California, USA
47. Kopelman P, DeGroot G, Rissanen A, et al. A randomized, placebo-controlled, trial of Cetilistat (ATL-962), a novel lipase inhibitor and orlistat for the management of obese type 2 diabetic patients. Diabetes Metab 2006;55(Suppl 1):A395
48. Sjodin et al. Effect of Tesofensine on energy metabolism and appetite, I J of Obesity, 34, 2010 (1634-1643)(c NeuroSearch. "Tesofensine". Available from: Http://www.neurosearch.dk/ Default.aspx?ID=118 [Last accessed 17 February 2011]
49. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition and quality of life in obese patients: A randomized, double-blind placebo controlled trial. Lancet 2008b;372:1906-13
50. Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: Perspective and current status. Eur J Pharmacol 2002;440:173-87
51. Shinogi press release. Shinogi announces positive top line efficacy results from year-long studies of Velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity. Available from: Http://www.shionogi.co. jp/ir-n/news/detail/e-090217-2.pdf [Last accessed February 2011]
52. Greenway RM, Schlossberg L, Dooley WC. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-95
53. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
54. Marcadia Biotech website. GIP/GLP- 1 dual agonist. Available from: Http:// www.marcadiabiotech.com/developmentprograms/ gipglp-1-dual-agonist.aspx [Last accessed 1 May 2011]
55. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med 2002;346(6):393-403
56. Sjostrom L, Narbro K, Sjostrom CD, et al. Effect of bariatric surgery on mortality in Swedish Obese subjects. N Engl J Med 2007;357(8):741-52